Neumora Therapeutics
NMRA
115 hedge funds and large institutions have $65.2M invested in Neumora Therapeutics in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 50 closing their positions.
117% more call options, than puts
Call options by funds: $282K | Put options by funds: $130K
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
9.45% less ownership
Funds ownership: 49.72% → 40.27% (-9.5%)
14% less funds holding
Funds holding: 134 → 115 (-19)
36% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 50
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
92% less capital invested
Capital invested by funds: $852M → $65.2M (-$786M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.19M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.4M |
| 3 |
Renaissance Technologies
New York
|
+$2.16M |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
+$1.88M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$42.4M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$39.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$22M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$10.1M |
| 5 |
O
OrbiMed
New York
|
-$8.53M |
NMRA Hedge Fund Activity: Q1 2025 in Review
115 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2025, worth a combined $65.2M — down 92% from $852M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of NMRA and 32 opened new positions — a net loss of 18 holders — while 30 trimmed existing stakes and 31 added.
The largest buyer was UBS Group, adding an estimated $3.19M. The largest seller was Deep Track Capital, exiting entirely with an estimated $42.4M sold.
- 115 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2025, down from 134 in Q4 2024.
- Funds reported $65.2M of Neumora Therapeutics stock for Q1 2025, down 92% quarter-over-quarter.
- 32 funds opened new Neumora Therapeutics positions in Q1 2025 and 50 closed out, a net change of -18 holders.
- The largest Neumora Therapeutics buyer in Q1 2025 was UBS Group, an estimated $3.19M added.
- The largest Neumora Therapeutics seller in Q1 2025 was Deep Track Capital, an estimated $42.4M sold.
Based on aggregated 13F filings for Q1 2025.